The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelm
Written by
in
The pharmaceutical company will give up its ownership rights to the drug and stop a clinical trial that had been aimed at confirming whether it works.
Written by
in